About Akonni
Akonni is a company based in Frederick (United States) founded in 2003. Akonni has raised $39.75 million across 50 funding rounds from investors including NIH, HHS and Ojp. The company has 12 employees. Akonni offers products and services including TruTip Nucleic Acid Universal Kit, TruPrepR Automated Sample Preparation System, and TruDiagnosis. Akonni operates in a competitive market with competitors including Somalogic, Nautilus Biotechnology, Inflammatix, Amunix and Visby Medical, among others.
- Headquarter Frederick, United States
- Employees 12
- SectorsHealthcare
- Website akonni.com
- Social LinkedIn
- Legal Name Akonni Biosystems, Inc.
- Total Equity Funding$39.75M (USD)
in 50 rounds
- Latest Funding Round$168.09K (USD), Grant
Sep 2021
- InvestorsNIH
& 5 more
- Employee Count12
Products & Services of Akonni
Akonni offers a comprehensive portfolio of products and services, including TruTip Nucleic Acid Universal Kit, TruPrepR Automated Sample Preparation System, and TruDiagnosis.
Robust technology for high-yield DNA and RNA extraction.
System providing higher purity for nucleic acid processing.
Integrated system for rapid multiplexed disease analysis.
Funding Insights of Akonni
Akonni has successfully raised a total of $39.75M across 50 strategic funding rounds. The most recent funding activity was a Grant round of $168.09 thousand completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $39.75M
- Total Rounds 50
- Last Round Grant — $168,087
- First Round $65,000
(Jul 2003)
- Investors Count 6
Latest 10 of 50 funding rounds of Akonni with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $168,087 | Grant | – | – | |
| Apr 2021 | $3.29M | Grant | – | – | |
| Jun 2019 | $1.78M | Series C | – | – | – |
| Aug 2018 | $3M | Grant | – | – | |
| Aug 2018 | $2.97M | Grant | – | – | |
| Aug 2018 | $1.11M | Series C | – | – | – |
| Feb 2018 | $7.5M | Series C | – | Righton | – |
| Jan 2018 | $2.36M | Series C | – | – | – |
| Sep 2017 | $2.35M | Series C | – | – | – |
| Mar 2017 | $4M | Series C | – | – | – |
6 investors in total: 6 institutional.
Investors in Akonni
Akonni has secured backing from 6 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and Ojp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Righton is associated with a brand presence online. | – | righton-oph.com | - | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
Scientific and technical information is managed and disseminated by OSTI.GOV. | – | osti.gov | Oak Ridge, United States | |
Federal justice system funding, training, and resources are provided. | – | ojp.gov | - |
Investor details for Akonni
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Akonni
8 people are tracked at Akonni (2 in leadership, 5 in board & advisors, 1 in team); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Jon Davis | President | Leadership |
Christopher Cooney | Vice President Of Product Development | Leadership |
David Keys | Director | Board & advisors |
Michael Farmer | Director | Board & advisors |
Tom McMahon | Director | Board & advisors |
Charles M. Parrish | Director | Board & advisors |
Myun Ki Han | Director | Board & advisors |
Arial Bueno | Sr. Electro-Mechanical Engineer | Team |
Complete people profiles for Akonni
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Akonni
3 dated milestones of Akonni across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Akonni is founded.
- Funding First funding round of $65K.
- Funding Latest funding round, Grant, of $168K.
Competitors of Akonni
Akonni operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Nautilus Biotechnology, Inflammatix, Amunix and Visby Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| inflammatix.com | 2016 | San Francisco, United States | $191.47M | 54 | Provider of diagnostic solutions for systemic infections | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. | |
| visbymedical.com | 2010 | San Jose, United States | $386.33M | 251 | Portable PCR diagnostics for infectious diseases are developed. | |
| me-med.com | 2009 | Tirat Carmel, Israel | $163M | – | Provider of machine learning based diagnostic solutions for infectious diseases | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| molbiodiagnostics.com | 2000 | Salcete, India | $123.98M | 714 | Point-of-care molecular platforms for infectious disease detection are developed. | |
| agendia.com | 2003 | Irvine, United States | $123M | 203 | Genomic diagnostic products for cancer treatment are provided. | |
| sunbirdbio.com | 2020 | Singapore | $14M | – | Diagnostic technologies for infectious, cancer, and neurological diseases are developed. |
Detailed competitors of Akonni
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Akonni
Complete news archive for Akonni
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Akonni
10 companies that operate in the same segment as Akonni (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Akonni
Akonni was founded in 2003.
Akonni is headquartered in Frederick, United States. It is registered at Frederick, Maryland, United States.
Akonni is a funded company, having raised a total of $39.75M across 50 funding rounds to date. The company's 1st funding round was a Series C of $4M, raised on Jul 2003.
Akonni has 12 employees.
Akonni Biosystem was founded in 2003 in Frederick, United States, and operates in the molecular diagnostics sector. Integrated systems for detecting complex infectious diseases, such as Methicillin-resistant Staphylococcus aureus, multi-drug-resistant tuberculosis, and oseltamivir-resistant influenza, are manufactured and marketed. The gel-drop microarray platform is utilized, with diagnostic tests and transportable readers provided for point-of-care applications in human health.
Akonni's top competitors include Somalogic, Visby Medical and Inflammatix.
Akonni offers TruTip Nucleic Acid Universal Kit, TruPrepR Automated Sample Preparation System, and TruDiagnosis.
Akonni has 6 investors. Key investors include NIH, HHS, Ojp, Righton, and National Science Foundation.
Akonni operates through Akonni Biosystems, Inc..